Skip to main content
Premium Trial:

Request an Annual Quote

RNAi Shop Nucleonics Secures $2.7M Investment from Oxford Finance

NEW YORK, Oct. 15 (GenomeWeb News) - RNAi-technology company Nucleonics has secured a $2.7 million equipment-financing investment from Oxford Finance Corporation, the company said this week.

Oxford Finance joins nine other venture capital funds that have already committed $50.8 million to support the development of Nucleonics' initial eiRNA therapeutic candidates for hepatitis B and C.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.